FGFR2‐Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape

BACKGROUND. With the exception of trastuzumab, therapies directed at receptor tyrosine kinases (RTKs) in gastroesophageal adenocarcinomas (GEA) have had limited success. Recurrent fibroblast growth factor receptor 2 (FGFR2) alterations exist in GEA; however, little is known about the genomic landsca...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Klempner, Samuel J., Madison, Russell, Pujara, Vivek, Ross, Jeffrey S., Miller, Vincent A., Ali, Siraj M., Schrock, Alexa B., Kim, Seung Tae, Maron, Steven B., Dayyani, Farshid, Catenacci, Daniel V.T., Lee, Jeeyun, Chao, Joseph
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Inc. 2019
Matèries:
Gastrointestinal Cancer
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6853122/
https://ncbi.nlm.nih.gov/pubmed/31249137
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0121
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars